Loading clinical trials...
Loading clinical trials...
Azacitidine in Combination With or Without All-trans Retinoic Acid in Newly Diagnosed Unfit Acute Myeloid Leukemia or Intermediate,High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R Criteria
Conditions
Interventions
Azacitidine
all trans retinoic acid
Locations
1
China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Start Date
May 1, 2021
Primary Completion Date
May 1, 2022
Completion Date
May 1, 2023
Last Updated
January 3, 2022
NCT03520647
NCT06859424
NCT06994676
NCT07450872
NCT06158828
NCT04645199
Lead Sponsor
The First Affiliated Hospital of Soochow University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions